# Study to Evaluate the Efficacy and Safety of SLV306 in Subjects With Hypertension

> **NCT00160212** · PHASE2 · COMPLETED · sponsor: **Solvay Pharmaceuticals**

## Conditions studied

- Hypertension

## Interventions

- **DRUG:** Daglutril

## Key facts

- **NCT ID:** NCT00160212
- **Lead sponsor:** Solvay Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-12
- **Primary completion:** —
- **Final completion:** —
- **Target enrollment:** — (—)
- **Last updated:** 2009-01-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00160212

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00160212, "Study to Evaluate the Efficacy and Safety of SLV306 in Subjects With Hypertension". Retrieved via AI Analytics 2026-06-10 from https://api.ai-analytics.org/clinical/NCT00160212. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*